MYB oncogene up-regulation is associated with estrogen receptor-positive (ER+) breast cancer (BRCA), but disease requirements for MYB function in vivo have not been explored. In this study we provide evidence of a critical requirement for MYB functions in models of human and murine breast cancer. In human BRCA, we found that MYB expression was critical for tumor cell growth both in vitro and in vivo in xenograft settings. In transgenic knockout mice, tissue-specific deletion of the murine Myb gene caused a transient defect in mammary gland development that was reflected in delayed ductal branching and defective apical bud formation.
Introduction
Breast cancer (BRCA) is heterogeneous in its genetic makeup and multifaceted in etiology (1) (2) . In addition to ERα, high expression of the receptor tyrosine kinase HER2 and the status of progesterone receptors are prognostic and therapeutic guides in BRCA management. Although the majority of BRCAs express one or more of these receptors, some are "triple-negative" (3); this subtype is often more aggressive and does not respond to conventional adjuvant therapies that target the above-mentioned receptors (4) (5) . With such phenotypic diversity, the prospect of identifying molecular points of convergence that drive BRCA may seem small although nonetheless enticing.
The appeal of considering transcription factors in the context of BRCA is that they are often downstream of multiple signaling pathways and their target genes can fall into promalignancy categories that cooperate in tumorigenesis. We have focused on the transcription factor, MYB (6) for which target genes in myeloid cells (7) and BRCA (8) have been reported.
A central observation that underpins our attention on MYB is that it is frequently overexpressed in BRCA (9) . We reported the direct regulation of MYB transcriptional elongation by ERα (6) , that MYB is essential for proliferation of BRCA cell lines (6) , and that it suppresses differentiation and apoptosis (10) . As ~70% of BRCAs are ERα+ve, this work addressed a significant BRCA category. Nevertheless, we report here that MYB is also evident in some HER+ve BRCA in the absence of ERα. At the other end of the spectrum are BRCA1-mutant BRCA (11) , representing only a few percent of all cases. Intriguingly however, 29% of BRCA1-mutant BRCA have amplified MYB (12) further suggesting that MYB has broad relevance to BRCA. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on September 26, 2011; DOI: 10.1158/0008-5472. CAN-11-1015 To specifically address the role of MYB in mammary cancer, we have now employed two transgenic mammary-specific tumor models. Both depend upon the mouse mammary tumor virus (MMTV) promoter to drive either the wild type (wt) rat NEU gene (13) or the Polyoma Middle T Antigen viral gene (PyMT) (14) . These models have provided many important insights into mammary cancer progression. We report here that with the specific ablation of MYB expression in the mammary gland, neither transgenic model progresses normally to form tumors. In vitro studies demonstrate that MYB protects mammary epithelial cells from apoptosis, allows colony formation in soft agar and drives cancer-associated gene expression. Collectively, these data establish a central and pervasive role for MYB in mammary carcinogenesis. 
Tumor Microarrays and Immunohistochemistry
Tumors (sixty-nine) from women without a family history of BRCA were collected with consent from a single site State Pathology Centre. These were processed for immunohistochemistry for HER2 (4B5; rabbit monoclonal Ventana), ERα (SP1; rabbit monoclonal Ventana) and pan-MYB (Mab1.1; Upstate Biotech) as described (17) , detected by horseradish-peroxidase conjugated anti-mouse or anti-rabbit secondary antibodies (DAKO), visualised with 3,3'-diaminobenzidine tetrachloride (DAKO), scanned (Aperio R slide scanner) and scored blinded by two observers. Mouse tissues were fixed in Methacan. Proliferating cell nuclear antigen (PCNA) was detected with mouse antibody PC-10 (Santa Cruz).
Cell culture and expression
Murine cell lines 67NR, 66cl4, 4T1, 4T1.2 were derived from a spontaneous mammary tumor Retroviral vectors pRufNeo-MYB (murine MYB, full length) and pRufNeo-Control were used to generate retroviral supernatants for stable transductions (20) . Western analysis of was conducted as previously described (21) (22) .
Anchorage independent growth
NMuMG MYB-transduced and control cells were plated in 0.35% agarose in 6 well plates (15,000 cells/well). Medium was added every 4-5 days and colonies photographed at day 21. 
Mammary gland analysis
Mammary glands whole mounts were spread on a glass slide before fixing in Carnoy fixative.
Glands were stained in 0.2% carmine and 0.5% aluminum sulfate overnight. Subsequent analysis was carried out using Metamorph R image software.
PCR
PCR was used to amplify genomic DNA for the detection of MYB f , Cre, and NEU genes (primers -Supplementary Table 1 ). For RT-qRT-PCR analyses, primers were designed using Primer Express software (Supplementary Table 2 ) and transcripts were amplified using a Prism 7000 Sequence Detection system (ABI).
FACS
Fluorescence activated cell sorting was used to detect apoptotic cells by Annexin V antibody binding (BD Pharmagen) and 7-amino-actinomycin D (7AAD) staining. Data were analyzed using the FCS express program (De Novo software).
Statistical Analysis
Data were subject to analysis using Graph-Pad Prism5 (CA, USA). 
Results

MYB Knock-down in vivo
Having established that MYB is required for proliferation of human ER+ve BRCA cells in vitro (6) we asked here if persistent expression was required for established tumors. ERα+ve ZR-75-1 cells with inducible shRNA directed against MYB (6) were generated with an eGFP expression module to allow in vivo xenograft imaging. Tumors were established orthotopically for two weeks before shRNA expression was induced with doxycycline ( Figure 1A 
MYB in HER2+ve/ERα-ve Breast Tumors
MYB expression is a consistent feature of ERα+ve BRCA; reviewed in (9) . We have shown above that it is required for growth in vivo. By evaluating BRCA from 69 women without a family history of BRCA in a TMA format we found most expressed MYB (64/69). colon epithelial homeostasis (27) . However they have not been employed to examine tumorigenesis in epithelial tissues. To ensure both efficient tumorigenesis as well as Cremediated recombination all females were subjected to two rounds of pregnancy and lactation.
All MMTV-NEU;MYB f/f females developed at least one mammary tumor between 300 -500 days consistent with other reports (13) . By contrast, at 500 days no MMTV-NEU;MMTVCre;MYB f/f females had palpable tumors. Later, three mice in this cohort of 14 mice developed tumors ( Figure 3C ) while the remaining mice died of old age, tumor-free. These late onset tumors from KO mice retained MYB expression albeit at lower levels (but higher than normal mammary glands) ( Figure 3D ) indicating that MYB was not completely deleted in these cases.
To ensure that the expression of the oncogenic MMTV-NEU transgene was not under the transcriptional influence of MYB in normal mammary tissue RNA (DNAse-treated) was prepared from adult female KO and wt mammary glands and subjected to qRT-PCR whereby rat NEU cDNA expression was found to be relatively robust and unaffected by the loss of MYB (Supplementary Figure 3A) .
MYB expression is required for timely MMTV-PyMT tumorigenesis
Given 
viable but have defects in mammary gland function (30) . We compared the expression patterns of MYB and A-MYB during mammary gland development compared to house keeping gene GAPDH ( Figure 5A) (and Cytokeratin-18; Supplementary Figure 4) expression. MYB expression was initiated earlier and at higher levels relative to A-MYB in virgin glands before it declined. Notably, luminal MYB is most evident in virgin glands (Figure 5B-D) and proportionally more cells were MYB+ve than those actively engaged in the cell cycle (PCNA+ve) or those that were ERα+ve (Supplementary Figure 5) . contrast to other KO mice such as CyclinD1, SRC and A-MYB which showed a lasting negative effect on mammary gland development (32) (33) . It is therefore reasonable to speculate that the delayed mammary development may be in part responsible for impeding a key event in the initiation of mammary carcinogenesis that is MYB-dependent
To test whether
MYB induces Anchorage-independent Growth and Enhances Cell Survival
We next sought to establish how MYB might contribute to mammary cell transformation.
We transduced NMuMG cells (26) 6A-B) . Under sub-optimal growth conditions (FCS 0.1%) NMuMG cells attach but show relatively poor growth in 2D culture, whereas MYB-transduced cell displayed robust growth ( Figure 6C ) associated with enhanced survival as assessed by AnnexinV staining (Figure 6D ).
The expression of two MYB-target genes associated with cell survival that are over-expressed and regulated by MYB in colorectal cancer and BRCA, Grp78/BIP and BCL-2 (10) were elevated (Figures 6E-F) . These data extend our previous findings that MYB suppresses differentiation and apoptosis of human BRCA cell lines (10). 
Discussion
The role for MYB in hematopoietic malignancies has overshadowed its important role in epithelial cancers (9) . RNA profiling studies collectively support the view that high MYB tracks with ERα+ve BRCA compared to most other epithelial cancers with the notable exception of colorectal cancers where MYB is not only over-expressed but also of prognostic importance (34) . Accordingly our focus has been on ERα+ve BRCA as this is the predominant subtype and we have made an important functional leap to show here the requirement for sustained MYB expression in established BRCA xenografts. We also showed that HER2+ve BRCA are MYB+ve.
To explore early events in mammary carcinogenesis, we turned our attention to mouse cell lines and transgenic models initially to evaluate MYB expression. In most instances we identified expression in excess of that found in immortalized mammary cells and mammary glands. With these data in mind we then had a rational basis to manipulate MYB expression in the mouse during mammary gland development and tumorigenesis.
The MMTV-promoter has been exploited extensively to drive gene expression and here we used the MMTV-Cre transgene to ablate MYB expression to assess its potential role in mammary gland development. We found that loss of MYB led to a delay in gland development, but most this difference was resolved in adult mice without a demonstrable consequence to fecundity or lactation. In the context of mouse mammary carcinogenesis, the earliest and a substantive advance made by Muller and colleagues was to drive the NEU gene with the MMTV promoter (13). Here we have shown that MYB is required for NEU-driven tumorigenesis in these mice. Previously we focused our attention on MYB in the context of ERα+ve BRCA but now we have to consider MYB in the broader context of HER2+ve BRCA. Thus this role in HER+ve BRCA which is the next most clinically tractable group to treat after ERα+ve BRCA further raises the importance of MYB more generally in BRCA. Indeed, recent analyses of BRCA expression profiling indicates that MYB is associated with high survival, particularly in patients with ERα+ve tumors (35) but that MYB did not track specifically with identified molecular subtypes such as basal, HER2, luminal A or B or normal-like BRCA. High MYB was also associated with improved survival in another study most obviously in luminal type BRCA bearing patients (36) . Together with our IHC data it seems that MYB expression arises in a range of BRCA sub-types. However, in contrast to an earlier pioneering report by Guerin et al (23) that emphasised an inverse relationship between HER2 and MYB where they still observed co-expression in 56% (24/56) and discordant expression in 77% (53/69) of noninflammatory BRCA we found by IHC that 92% HER+ve BRCA co-expressed MYB (12/13).
ERα expression was present in 9/13 HER+ve BRCA that we examined however MYB and HER2 can be co-expressed in the absence of ERα (4/13 HER2+ve tumors).
This relationship between MYB and mammary carcinogenesis is not without complexities as the MMTV-PyMT mouse data suggested. In these mice we found that although MYB was required for the normal kinetics of tumorigenesis its ablation did not stop tumor formation in three-quarters of female mice and indeed the tumors that arose were both MYB high and low. Conversely, in the absence of this genetic selection most tumors that arose in MMTV-PyMT mice had detectable MYB expression but the levels were variable. These data suggested that MYB was required for the timely development of mammary tumors but was not 
ultimately essential for their progression. Certainly we and others have reported that MYB is not in all BRCA cell lines; MDA-MB-231 being a notable ERα-ve and MYB-ve cell line (6) and 15/133 BRCA were MYB-ve in the TMAs (Supplementary Figure 1) . However, the link between these models might be that mammary tumorigenesis may proceed through an ERα-dependent phase where PyMT but not NEU expression may more readily progress in the absence of MYB.
In vitro studies were used to demonstrate that MYB modifies the growth of immortalized mammary cells and activates genes associated with cell survival. To probe the functional role of MYB during mammary gland tumorigenesis, the normal mammary epithelial cell line NMuMG expressing full-length MYB was assessed for the expression of established MYB target genes, Grp78, and BCL-2, which were found to be consistently up-regulated. NMuMG cells transduced with MYB showed enhanced proliferation and reduced apoptosis likely to be due to the elevated expression of these pro-survival genes (37) . However elevated MYB did not alter cell migration as measured by the scratch assay (data not shown).
Although many studies have documented MYB target genes (9) less is known about the mechanisms that regulate MYB expression itself. Certainly the MYB promoter is subject to regulation by the PI3 kinase and AKT pathway in T-cells (38) and can be auto-regulated by MYB itself (39) (40) . Beyond promoter activation a principle mechanism of MYB regulation is the ability of exon-1 transcripts to be extended by transcriptional elongation (41) (42) (43) (44) and in the case of colon cancer, we have shown that mutations in a region that regulates this process are relatively common in the human gene (9) . However similar mutations were not detected in human BRCA or cell lines (42), rather we found that the ERα when bound by estradiol 
